7048 J. Med. Chem. 2010, 53, 7048–7060
DOI: 10.1021/jm1006676

Journal of Medicinal Chemistry Article

Synthesis and Biological Evaluation of Bivalent Ligands for the Cannabinoid 1 Receptor

Yanan Zhang,*[,†] Anne Gilliam,[†] Rangan Maitra,[†] M. Imad Damaj,[‡] Julianne M. Tajuba,[†] Herbert H. Seltzman,[†] and Brian F. Thomas*[,†]

[†]*Research Triangle Institute, Research Triangle Park, North Carolina 27709, and* [‡]*Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298*

Received June 2, 2010

Dimerization or oligomerization of many G-protein-coupled receptors (GPCRs), including the cannabinoid 1 (CB1) receptor, is now widely accepted and may have significant implications for medications development targeting these receptor complexes. A library of bivalent ligands composed of two identical CB1 antagonist pharmacophores derived from SR141716 linked by spacers of various lengths were developed. The affinities of these bivalent ligands at CB1 and CB2 receptors were determined using radiolabeled binding assays. Their functional activities were measured using GTP-γ-S accumulation and intracellular calcium mobilization assays. The results suggest that the nature of the linker and its length are crucial factors for optimum interactions of these ligands at CB1 receptor binding sites. Finally, selected bivalent ligands (**5d** and **7b**) were able to attenuate the antinociceptive effects of the cannabinoid agonist CP55,940 (**21**) in a rodent tail-flick assay. These novel compounds may serve as probes that will enable further characterization of CB1 receptor dimerization and oligomerization and its functional significance and may prove useful in the development of new therapeutic approaches to G-protein-coupled receptor mediated disorders.

Introduction

The endocannabinoid system (ECS) comprises the cannabinoid 1 (CB1[a]) and cannabinoid 2 (CB2) receptors, their endogenous ligands (endocannabinoids), and the proteins involved in endocannabinoid synthesis and inactivation, as well as the intracellular signaling pathways affected by endocannabinoids.[1] Increasing evidence suggests that the endocannabinoid system is critically involved in a variety of physiological and pathological conditions. More importantly, modulation of the endocannabinoid system may hold therapeutic promise to treat a wide range of disparate diseases such as pain, inflammatory diseases, peripheral vascular disease, appetite enhancement or suppression, and locomotor disorders.[2] The CB1 receptor, which belongs to the G-protein-coupled receptor (GPCR) superfamily, the largest class of cell surface receptors, is believed to mediate most of the actions exerted by exogenous cannabinoids or endocannabinoid in the brain.[3]

While GPCRs were traditionally considered monomeric, it is now well accepted that many GPCRs, including the CB1 receptor,[4,5] exist on the cell membrane as homo- and heterodimers or higher-order oligomers.[6] Moreover, receptor oligomerization is often essential for receptor function (e.g., the GABAB receptor)[7] and can also modulate ligand interaction, activation, signal transduction, and internalization.[8−12] For example, it has been proposed that a $\mu-\delta$ opioid receptor heterodimer is the fundamental signaling unit that mediates opioid tolerance and dependence through specific signal transducer(s) that recognize and couple to the heterodimer but not to μ-receptor monomers/homomers.[13] In an analogous fashion, modulation of the CB1 receptor dimers or oligomers may offer novel opportunities to uniquely target and manipulate function of the endocannabinoid system.

The importance of GPCR dimerization and oligomerization in vivo remains to be elucidated and exploited, largely because of a lack of selective pharmacological tools and immunological reagents. Among various efforts to modulate GPCR oligomers, bivalent ligands, which are defined as two pharmacophores linked by spacers, represent a unique and promising approach and may provide such a tool.[14,15] Bivalent ligands, provided they have suitable functional affinity at the monomeric receptor, are expected to selectively bind with greatly enhanced affinity to ligand recognition sites on heterodimers and oligomers because of the small containment volume for the second pharmacophore after the binding of the first one and the formation of thermodynamically more stable complexes. At the same time, bivalent ligands may display unique properties, since they interact with more than one receptor simultaneously. Indeed, bivalent ligands have been developed for variety of G-protein-coupled receptor targets, including opioids,[14,16] adrenergic,[17,18] dopamine,[19] serotonin,[20,21] and muscarinic receptors.[22,23] These bivalent ligands have been shown to be able to selectively target homo- or heterodimers and display unique pharmacological properties compared to their monomeric subunits. However, to the best of our knowledge, there are no bivalent ligands developed for the CB1 receptor to date.

*To whom correspondence should be addressed. For Y.Z.: phone, 919-541-1235; fax, 919-541-6499; e-mail, yzhang@rti.org. For B.F.T.: phone, 919-541-6552; fax, 919-541-6499; e-mail, bft@rti.org.

[a]Abbreviations: GPCR, G-protein-coupled receptor; CB1, cannabinoid 1 receptor; CB2, cannabinoid 2 receptor; SAR, structure−activity relationship; CNS, central nervous system; BOP, benzotriazole-1-yl-oxytris(dimethylamino)phosphonium hexafluorophosphate; HOBt, 1-hydroxybenzotriazole; EDCI, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide; THF, tetrahydrofuran; DMSO, dimethylsulfoxide; DMF, dimethylformamide; CDI, carbonyldiimidazole; TLC, thin-layer chromatography; NMR, nuclear magnetic resonance.

 Published on Web 09/16/2010



Figure 1. Compound **1** and 3-substituted analogues with alkyl or polar linkers.

Here we present our efforts in the design and synthesis of symmetrical bivalent ligands targeting CB1 receptor dimers. The bivalent ligands contain two identical core structures of 1,5-diarylpyrazole derived from **1** (SR141716, or rimonabant, Figure 1) joined by a variety of linkers. Compound **1** was initially reported by Sanofi-Recherche as a highly potent and selective CB1 receptor antagonist/inverse agonist. It was the first drug to selectively block both the in vitro and in vivo effects of cannabinoids that are mediated by the CB1 receptor. Compound **1** was approved for the treatment of obesity in Europe before its recent withdrawal from the market because of undesirable psychological effects. This compound also shows great promise in many potential therapeutic applications including smoking addiction, drug and alcohol dependence, cognitive disorders, inflammation, and arthritis.[24,25] By developing bivalent ligands with **1** as the pharmacophore, we aim to affect the binding affinities of these ligands to cannabinoid receptor monomers/dimers and perhaps alter their efficacies or signal transduction pathways as antagonists/inverse agonists. We hereby describe the synthesis and preliminary pharmacological examination of a series of bivalent ligands that possess linkers of various lengths and describe the results with respect to the optimal linker length for affinity and their related pharmacological activity using various pharmacological approaches. For comparative purposes, corresponding monovalent ligands were synthesized to evaluate the contribution of the presence of the linkers to activity.

Results

Bivalent Ligand Design. In order to focus our efforts on the efficient development of bivalent ligands, we selected **1**, a prototypical CB1 receptor antagonist/inverse agonist. In addition to the high affinity and potency at the CB1 receptor in vitro and in vivo, the structure−activity relationships on this class of compounds have been well studied and documented. This allowed for an informed selection of appropriate positions to attach the linkers to the molecules without likely eliminating their affinity or decreasing their efficacy or activity significantly. It also permitted efficient synthesis following known procedures with minimal modifications. In particular, SAR results on this structure class indicate that the 3-carboxyamide position generally tolerates the replacement of the 1-aminopiperidyl group with a variety of substituents including alkyl groups and aromatic groups (**2**, Figure 1).[26−28] Therefore, bivalent ligands linked through the 3-position were initially developed.

A series of bivalent ligands with 3-position linkers of varying lengths were synthesized and evaluated in efforts to optimize the linker length for bridging of the receptors dimers. The optimal linker lengths, or the distances between the binding sites on neighboring receptors in receptor dimers or oligomers, have been reported on a number of GPCRs. Molecular modeling studies based on the crystal structure of rhodopsin suggested a distance between the individual receptors to be ~35 Å, although the receptor dimer was in a head-to-tail orientation.[29] Similarly, molecular modeling on the opioid receptor suggested that the distance between the recognition sites of either the interlocking or contact dimers with a TM5,6-interface is ~27 Å, while it is greater (~32 Å) in dimers with TM4,5-interface.[14] However, during their studies on opioid bivalent ligands, Portoghese and co-workers discovered that optimal activity was obtained when spacers are about 22 Å (~19 atoms).[30] On the other hand, Neumeyer and co-workers found that bivalent ligands for the opioid receptors having spacers containing 10 methylene units or less displayed the highest affinities.[31,32] More recently, a series of adenosine A_{2A} antagonist/dopamine D_2 agonist bivalent ligands were developed where linkers ranged between 26 and 66 atoms.[33] Interestingly, affinities of the bivalent ligands to both receptors stayed almost identical with the elongation of the linkers. The authors indicated that linkers with 26 atoms were of sufficient length to allow the bivalent ligands to bind to receptor dimers according to receptor docking experiments and suggested that the lack of correlation between binding affinity and linker length might be due to the high flexibility of the mixed peptide/polyethylene glycol linkers. On the basis of these findings and others, linkers between 5 and 23 atoms were initially examined in our laboratory to determine optimal linker length.

Three types of linkers have been considered in the design of the bivalent ligands. The first class investigated was polyethylene glycol linkers. The second category is composed of small peptides (Figure 1). These two classes of linkers have been employed in bivalent ligand development by a number of groups.[14,23,34] Not only are these linkers readily available but they also offer the advantage of gradually increasing the



Figure 2. Bivalent and monovalent ligands with triamine linkers.

Scheme 1. Synthesis of Compounds **3** and **4**[a]



[a]Reagents and conditions: (a) benzotriazole-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), 1,11-diamino-3,6,9-trioxaundecane, THF; (b) glycine methyl ester hydrochloride, HOBt, EDCI, Et_3N, CH_2Cl_2; (c) NaOH, MeOH/H_2O; (d) LiOH, THF/MeOH/H_2O; (e) ethylenediamine, HOBt, EDCI, Et_3N, CH_2Cl_2.

linker length. However, our preliminary results with these two types of linkers failed to show promise. Both compounds **3** and **4** had low affinity in radiolabeled binding and were inactive in GTP-γ-S and calcium assays (data not shown). This is consistent with literature results that suggest that hydrophobic groups are generally preferred at this 3-carboxamide position of **1**.[26,27,35] Linkers composed of alkylamines were also examined (Figure 2). The selection of these hydrophobic molecules was based on the SAR studies in our laboratory and also by Wiley and co-workers that indicate that substitution of the 3-carboxamide with hydrocarbons usually retains or sometimes even improves the affinity or antagonist activity of **1**.[26,27,35] Accordingly, a series of alkyltriamines were selected to construct the bivalent ligands (**5a**−**f**, Figure 2). A protonatable nitrogen atom was introduced in the middle of the chain in order to reduce the incremental increases in hydrophobicity upon elongation of the alkyl chains. This nitrogen not only provides symmetry of the bivalent ligands but also facilitates the construction of long alkyl linkers. Additionally, the *N*-methyl series of analogues (**6a**−**d**) were prepared to examine the possible hydrogen bonding effects of the alkylamine linker.

Chemistry. Compound **3** was obtained by coupling between the pyrazole carboxylic acid (**9**), which was readily prepared from commercially available 4-chloropropiophenone in three steps, following the procedure developed in our laboratory,[36,37] and 1,11-diamino-3,6,9-trioxaundecane using benzotriazole-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) as the coupling agent (Scheme 1). In the preparation

Scheme 2. Synthesis of N−H Triamine Linkers **18c**−**f**[a]



[a]Reagents and conditions: (a) NaCN, K_2CO_3, DMSO; (b) benzylamine, K_2CO_3, 1-butanol or DMF, 100 °C; (c) H_2, Raney nickel, ethanol, 2 N NaOH; (d) H_2, Pd/C, ethanol.

Scheme 3. Synthesis of Bivalent Ligands **5a**−**f** and Monovalent Ligands **7a**−**f**[a]



[a]Reagents and conditions: CDI (0.5 equiv for **5a**−**f**, 3 equiv for **7a**−**f**), CH_2Cl_2.

of **4**, acid **9** was coupled to glycine methyl ester hydrochloride under standard coupling conditions that employed hydroxybenzotriazole (HOBt), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), and triethylamine in tetrahydrofuran[38] to give the methyl ester (**10**) in almost quantitative yield. Hydrolysis of **10** in methanolic sodium hydroxide at room temperature furnished **11** in quantitative yield. Coupling of **11** with glycine methyl ester hydrochloride under identical conditions as that of **9**, followed by mild hydrolysis (LiOH, MeOH/THF/H_2O), provided **12** in excellent yield. Finally, reaction of **12** with excess ethylenediamine furnished **4**.

The route to bivalent ligands **5a**−**f** and monovalent ligands **7a**−**f** required the use of the N−H triamine linkers **18a**−**f**. While **18a**,**b** were commercially available, **18c**−**f** were prepared in our laboratory as shown in Scheme 2. For **18c**−**d**, the starting bromoalkylnitriles (**15c**−**d**) were commercially available. Intermediates **15e** (m = 8) and **15f** (m = 10) in the preparation of **18e**−**f** needed to be synthesized from dibromides **13** and **14**, respectively. This was readily accomplished by displacing one of the bromides in these dibromoalkanes with a cyano group using sodium cyanide in dimethylsulfoxide (DMSO). Thereafter, bis-alkylation of benzylamine with bromides **15c**−**f** in the presence of potassium carbonate in 1-butanol or dimethylformamide (DMF) furnished amines **16c**−**f** in excellent yields. Reduction of these nitriles was readily accomplished by hydrogenation catalyzed with Raney nickel to give **17c**−**f**. Another hydrogenation using palladium on carbon removed the benzyl groups to afford triamines **18c**−**f**, which were generally of sufficient purity and were used in the following step without further purification. It is worth noting that the sequence of the hydrogenations was important and debenzylation

followed by reduction of nitriles failed to give the desired products in satisfactory yields.

The coupling of acid **9** and triamines **18a−f** was then attempted using several methods in order to furnish the bivalent ligands. Initial trials on the coupling employing the acid chloride or activation of acid **9** with agents such as chloroformates or BOP all failed to display selectivity, and products with acylation at all three amino sites were obtained as the primary products. Eventually carbonyldiimidazole (CDI) appeared to provide satisfactory selectivity, and the desired products **5a−f**, where acylation occurred at the two primary amino sites, were obtained in reasonable yields (Scheme 3). Under similar conditions, acylation at only one of the primary amino groups could be readily accomplished with the employment of excess triamines **18a−f** to provide **7a−f**.

Scheme 4. Synthesis of N−Me Bivalent Ligands **6a−d** and Monovalent Ligands **8a−d**[a]



[a]Reagents and conditions: (a) methylamine in methanol or methylamine hydrochloride, K_2CO_3, ethanol, microwave or heated in pressure tube; (b) H_2, Pd/C, ethanol; (c) CDI (0.5 equiv for **6a−d**, 3 equiv for **8a−d**), CH_2Cl_2.

Following a procedure analogous to that of Scheme 2, the *N*-methyltriamine linkers were prepared as depicted in Scheme 4. Bis-alkylation of methylamine in methanol or methylamine hydrochloride with bromides **15c−f** in ethanol under microwave conditions or heated in sealed pressure tubes provided **19a−d** in almost quantitative yields. Hydrogenation catalyzed by palladium on carbon provided the triamines (**20a−d**) in excellent yields. Similar to Scheme 3, the *N*-methyl bivalent ligands **6a−d** and the monovalent controls **8a−d** were obtained by coupling reactions between acid **9** and amines **20a−d** using CDI.

Binding Affinities of Synthesized Compounds. All the target compounds were evaluated in competition binding assays using both rat whole brain membrane preparations and cells stably transfected with either the human CB1 or CB2 receptors. The receptor binding affinities were determined in competitive displacement assays using radioligands [^{3}H]**1** and [^{3}H]CP55,940 (**21**). The results are summarized in Tables 1 and 2.

Most of the bivalent ligands displayed nanomolar affinity at the CB1 receptor, albeit somewhat lower than the parent compound **1**. Similarly to **1**, all bivalent ligands and monovalent controls also showed reasonable selectivity for the CB1 receptor over the CB2 receptor, displaying little or no affinity at the CB2 receptor. Noticeably, all compounds exhibited higher affinity (2- to 3-fold) for the CB1 receptor in the displacement of [^{3}H]**1** than the structurally different [^{3}H]**21**. This is in agreement with observations previously reported by Wiley and co-workers where derivatives of **21** were usually better ligands in displacement of radiolabeled **21** than **1**.[39]

Table 1. Binding Affinities of N−H Bivalent Ligands **5a−f** and **7a−f** against [^{3}H]**21** and [^{3}H]**1**

compd	*n*	linker (atoms)	displacement assay vs tritiated ligands: K_i (nM) in hCB1 ($n = 2$) [^{3}H]**21**	SEM	[^{3}H]**1**	SEM	displacement vs [^{3}H]**21**: K_i (nM) in hCB2	CB1/CB2
1			6.18	1.2	1.18	0.1	313	50.6
5a	2	5	229	75.0	94.0	8.00	1285	5.6
5b	3	7	174	1.0	41.9	5.40	496	2.9
5c	5	11	68.1	12.6	30.4	4.40	451	6.6
5d	7	15	12.3	1.10	4.41	0.34	553	45.0
5e	9	19	54.1	16.3	57.4	44.7	*a*	>46
5f	11	23	99.3	35.8	37.0	4.55	*a*	>25
7a	2	5	1225	359	506	56.5	*a*	>2
7b	3	7	*a*		*a*		*a*	
7c	5	11	349	36.5	230	4.50	*a*	>7
7d	7	15	46.7	1.85	19.5	1.35	622	13.3
7e	9	19	14.0	2.10	5.44	0.62	419	29.9
7f	11	23	4.56	0.83	2.30	0.20	305	66.9

[a] K_i is greater than the highest standard of 2500 nM.

Table 2. Binding Affinities of N−Me Bivalent Ligands **6a−d** and Monovalent Ligands **8a−d** against [^{3}H]**21** and [^{3}H]**1**

compd	*n*	linker (atoms)	displacement assay vs tritiated ligands: K_i (nM) in hCB1 ($n = 2$) [^{3}H]**21**	SEM	[^{3}H]**1**	SEM	displacement vs [^{3}H]**21**: K_i (nM) in hCB2	CB1/CB2
6a	5	11	38.7	4.0	6.35	1.07	1037	26.8
6b	7	15	17.3	0.45	27.5	1.90	683	39.5
6c	9	19	247	29.0	94.1	25.9	*a*	>10
6d	11	23	1885	450	1292	524	*a*	>1.3
8a	5	11	162	22.5	88.8	0.45	*a*	>15
8b	7	15	37.5	4.45	15.5	0.40	1934	51.6
8c	9	19	10.0	1.27	6.12	1.06	265	26.5
8d	11	23	14.7	5.27	5.51	1.81	426	29.0

[a] K_i is greater than the highest standard of 2500 nM.

Table 3. Functional Assessment of the Alkyl N−H Series of Bivalent Ligands **5a**−**f** and Monovalent Ligands **6a**−**f** at the CB1 Receptor[e]

		GTP-γ-S assay in rat brain		GTP-γ-S assay in hCB1		GTP-γ-S assay in hCB1		calcium assay	
compd	linker	EC_{50} (nM)	E_{max} (%)	EC_{50} (nM)	E_{max} (%)	PA_2 in hCB1	±95% confidence limits	K_e (nM)	SEM
1		56305	−37.8	ND		8.59	0.08	1.1	0.12
5a	5	*b*	−35.9	237	−25.5	7.08	0.52	2702	411
5b	7	718	−37.2	84.2	−31.9	7.41	0.27	1304	279
5c	11	*b*	−29.6	33.0	8.5	7.53	0.28	476	69
5d	15	1193	−25.0	179	−38.8	8.08	0.24	567	64
5e	19	1.34	10.4	27.9	6.5	7.76	0.60	4165	1142
5f	23	*b*	−12.2	*a*		7.56	0.35	*d*	
7a	5	7243	−22.9	ND		*c*	*c*	*d*	
7b	7	*b*	−34.8	ND		*c*	*c*	*d*	
7c	11	2222	−40.7	ND		6.12	0.32	5399	1105
7d	15	3279	−52.8	ND		7.69	0.46	502.6	225
7e	19	2393	−65.2	ND		8.25	0.28	31.6	3.1
7f	23	3616	−29.2	ND		8.50	0.26	146.5	19.1

[a] EC_{50} is greater than the highest standard of 25 000 nM. [b] EC_{50} is greater than the highest standard of 10 000 nM. [c] Does not converge, unable to calculate value. [d] No shift observed at 10 000 nM. [e] ND: not done.

Table 4. Functional assessment of the N-Me series of bivalent ligands **6a**−**d** and monovalent ligands **8a**−**d** at the CB1 receptor

		GTP-γ-S assay in rat brain		GTP-γ-S assay in hCB1		GTP-γ-S assay in hCB1		calcium assay	
compd	linker	EC_{50} (nM)	E_{max} (%)	EC_{50} (nM)	E_{max} (%)	PA_2 in hCB1	±95% confidence limits	K_e (nM)	SEM
6a	11	1.78	−3.8	59.8	−13.1	7.96	0.22	107.7	20.8
6b	15	1460	−40.8	2238	−32.7	8.37	0.24	478.3	14.3
6c	19	*b*		161	−23.0	7.53	0.25	*c*	
6d	23	29.3	17.3	*a*		6.30	0.32	*c*	
8a	11	3037	−53.3	ND		6.51	0.77	2873	418
8b	15	4367	−62.0	ND		7.66	0.55	219.8	2.8
8c	19	3404	−67.9	ND		8.34	0.25	140.9	29.1
8d	23	8768	−49.3	ND		7.63	0.65	205.5	2.9

[a] EC_{50} is greater than the highest standard of 25 000 nM. [b] EC_{50} is greater than the highest standard of 10 000 nM. [c] No shift observed at 10 000 nM.

Interestingly, the binding affinity of the N−H bivalent ligand series at the CB1 receptor appeared to be sensitive to the length of the linkers (Table 1). Specifically, the affinity initially increased with increasing linker length and then decreased as the linker was extended. The peak affinity was obtained with **5d** (n = 7), where the linker is composed of 15 atoms, against both radioligands (K_i of 12.3 nM vs [^{3}H]**21** and 4.41 nM vs [^{3}H]**1**). A different pattern was observed for the corresponding monovalent controls in this series (**7a**−**f**, Table 1), where the affinity increased as the spacer became longer, with the most potent compound determined to be **7f** (n = 11, 23 atoms, K_i of 4.56 nM vs [^{3}H]-**21** and 2.30 nM vs [^{3}H]-**1**).

A similar trend in affinity was also observed in the bivalent ligands of the N−Me series (**6a**−**d**, Table 2) with respect to their ability to compete for [^{3}H]**21** and [^{3}H]**1** binding. Affinity initially increased with linker length, with **6a** (n = 5) and **6b** (n = 7) displaying the greatest ability in displacing either [^{3}H]**1** or [^{3}H]**21**. Slightly different from the N−H monovalent ligand series, the binding affinity of *N*-methyl monovalent controls (**8a**−**d**) at the CB1 receptor initially increased and then remained relatively constant with the elongation of the linker, with **8c** and **8d** displaying almost identical K_i values. Interestingly, when the linkers are of the same length, the affinities of the bivalent ligands from both the N−H and N−Me series are relatively similar, indicating that the presence of the *N*-methyl group did not appear to interfere with the interaction of the bivalent ligands with the receptors.

Inverse Agonist/Antagonist Activity. All compounds were examined in vitro using both [^{35}S]GTP-γ-S accumulation and intracellular calcium mobilization assays to characterize their efficacy, inverse agonist activity, and apparent affinity (pA_2). The results are shown in Tables 3 and 4.

In the [^{35}S]GTP-γ-S assay using whole rat brain, most dimers and monomers appeared to act as weak inverse agonists. Similar to **1**, most compounds required micromolar concentrations to show inverse agonist activity in hCB1 transfectants, and the change from basal activity was relatively modest (< 25% decrease in basal binding under the conditions used). However, most compounds potently shifted the concentration−response curve of the agonist **21**, indicating that they were high affinity antagonists. Significantly, the pA_2 values against **21** stimulated [^{35}S]GTP-γ-S binding in hCB1 cells were correlated with their K_i values in both the N−H and N−Me series. Specifically, the pA_2 values first increased and then decreased for the bivalent ligands and always increased for the monovalent ligands. The bivalent ligand with the highest apparent affinity in the N−H series was **5d**, whereas **6b** showed the highest pA_2 value in the N−Me series. The higher potencies of the bivalent ligand **5d** and **6b** than the monovalent ligands **7d** and **8b**, respectively, is consistent with the binding affinities of these bivalent ligands.

All the compounds were also tested using a calcium mobilization assay as a measure of CB1 receptor function and again showed nanomolar potency. The same trend of an initial increase followed by a subsequent decrease in potency with increasing linker length was observed for bivalent ligands in both series (**5a**−**f** and **6a**−**d**), with the exception of **6a**, whereas the potency generally increased and stayed consistent for the monovalent ligands (**7a**−**f** and **8a**−**d**). Compounds **5c** and **5d** showed the greatest potency in N−H bivalent ligands, and **6a** was the most potent N−Me bivalent ligand. However, no potency enhancement at the optimal linker (15 atoms) was observed in this assay between the bivalent and monovalent ligands (**5d** vs **7d** and **6b** vs **8b**).



Figure 3. Blockade of the antinociceptive effect of **21** by bivalent and monovalent ligands. Results are expressed as the percent maximal possible effect (% MPE, where % MPE = [(test_control)/(maximum latency_control) × 100]) as defined by a 10 s cutoff for the noxious stimulus. Significant differences ($p < 0.05$) from vehicle-**21** treated controls are denoted with an asterisk (∗).

Tail-Flick Studies of Selected Ligands. The bivalent ligands with the highest affinity and potency, **5d** and **6b**, and their monovalent controls, **7d** and **8b**, were evaluated for their ability to block the antinociceptive effects of the cannabinoid agonist **21** in a rodent tail-flick assay. In the experiment, the tail was exposed to 55 °C warm water and the amount of time taken for the animal to move (flick) its tail away from the heat was recorded. Test compounds or vehicle were administered at 10 mg/kg ip to male mice 30 min prior to the administration of vehicle or 1.5 mg/kg **21**. Tail-flick times were measured 30 min after treatment with **21**. Antinociceptive response was calculated as percentage of maximum possible effect. As shown in Figure 3, a single 10 mg/kg ip dose of the bivalent ligand **6b** and its monomeric control **8b** could significantly attenuate the antinociceptive response to **21**. However, the N−H analogues (**5d** and **7d**) were considerably less active.

Discussions and Conclusions

The concept of homo- and heterodimerization has opened new potential avenues for the development of drugs targeted at GPCRs. One emerging approach is to employ bivalent ligands that specifically bind to these receptor dimers. Ideally, bivalent ligands with linkers of optimal length will bind to receptor dimers with greatly enhanced affinity due to the formation of thermodynamically stable complexes. Indeed, significant progress has been made in a number of GPCRs including opioids,[14,16] adrenergic,[17,18] dopamine,[19] serotonin,[20,21] and muscarinic receptors.[22,23] Most significantly, much success has been recently achieved by Portoghese and co-workers with bivalent opioid ligands in vivo.[40,41] In particular, μ-opioid (MOP) agonist/δ-opioid (DOP) antagonist bivalent ligands were shown to be potent analgesics after systemic administration but did not produce the tolerance or dependence seen with traditional monovalent opioid analgesics.[13] However, to the best of our knowledge, there are no bivalent ligands developed for the CB1 receptor to date. It is now well established that this receptor is a viable target to treat various indications including smoking addiction, drug and alcohol dependence, metabolic syndrome, cancer, fibrosis, and inflammation. The consequences of altered cellular function as a result of dimerization and oligomerization of CB1 receptors are being explored. The availability of high affinity bivalent ligands for CB1 receptors may provide researchers the necessary probes to identify the physiological importance of such interactions and further our understanding of the role of cannabinoid signaling in the context of health and disease.

In the present study, we synthesized a library of symmetrical bivalent ligands containing two moieties of **1** joined by aminoalkyl linkers. All the target compounds were evaluated in radiolabeled binding assays at the CB1 and CB2 receptors, functional [^{35}S]GTP-γ-S accumulation assay, and functional calcium mobilization assay. Data from these in vitro assays displayed subtle differences between K_i, pA_2, and K_e values. This is not surprising, as different end points and biological systems were experimentally employed for ligand characterization. Interestingly, a clear trend could be detected in all three assays where the bivalent ligands showed initially increased and then decreased affinity/activity with elongation of the linkers, whereas the monovalent ligands generally continued increasing or stayed consistent once the linker length was sufficiently long.

Such an initial increase, followed by a subsequent decrease in affinity and potency of the bivalent ligands, is consistent with observations in the bivalent opioid ligands made by the Portoghese and Neumeyer groups.[14,31,42,43] Thus, it is hypothesized that linker length is critical for the ability of the bivalent ligands to bind the CB1 receptor, possibly two neighboring CB1 receptors simultaneously, as insufficient length would not permit bridging and spacers of excessive length would reduce bridging because of increased confinement volume. This transition suggests that bridging of vicinal receptors by bivalent ligands may occur most efficiently with optimal linker length. This hypothesis is also supported by the different pattern that was observed for the corresponding monovalent controls in this series (**7a**−**f**, Table 1), where the affinity increased as the spacer became longer, with the most potent compound determined to be **7f** (n = 11, 23 atoms).

Most interestingly, the highest affinity bivalent ligand (**5d**), where the linker is composed of 15 atoms, displays higher affinity (~4-fold for both radioligands) than the corresponding monovalent control (**7d**), indicating that the presence of the second pharmacophore increases the ability for the

compounds to bind to the receptor, possibly by simultaneous occupying vicinal recognition sites of neighboring receptors in the receptor dimer. Again, this affinity enhancement of bivalent ligands over their corresponding monovalent ligands has been widely observed in previous studies on the opioid receptors, although it is often a modest (~2-fold) difference.[31] It is worth noting that despite the moderate affinity or potency enhancement observed for the bivalent over the monovalent ligands in the binding or functional assays, additional evidence in support of the homodimers binding hypothesis has been reported using techniques such as FRET, as demonstrated by Russo and co-worker in 5-HT_4 receptors.[20] The optimal linker length of 15 atoms in the present study is consistent with the range reported for bivalent ligands developed for other GPCRs.[30,31,40,44]

While these data indicate possible binding of the bivalent ligands to CB1 receptor homodimers, the fact that monovalent ligands display comparable or even higher affinity than the corresponding bivalent ligands when the linker is sufficiently long (**5e**,**f** vs **7e**,**f**, and **6c**,**d** vs **8c**,**d**) raises other possibilities. Indeed, the observation that monovalent ligands are more potent than the bivalent ligands has also been previously reported in bivalent ligands for other GPCRs including opioids, 5-HT_4 and GnRHR.[20,31,34,45−47] A single receptor binding model has been presented in opioid bivalent ligands which suggests that the linker itself may represent an additional receptor recognition site and only one pharmacophore is needed when the spacer is of sufficient length.[14,48] This hypothesis may also be supported by the observation that no relationship between the linker length and binding affinity was discovered in bivalent opioid ligands where the highest affinity ligands were at opposite extremes of linker length.[46] It is worth noting that hybrid ligands designed to target single GPCRs have been developed.[49−51] Named bitopic or dualsteric ligands, these compounds possess pharmacophores for an orthosteric site and an allosteric site, respectively, and are capable of binding single receptors with enhanced affinity and/or selectivity for several GPCRs, including the muscarinic acetylcholine receptors[49,52] and the adenosine A1 receptor.[53] Therefore, further studies are clearly needed to elucidate the binding mechanism of our CB1 bivalent ligands.

Finally, selected bivalent ligands (**5d** and **7b**) and the corresponding monovalent controls (**6d** and **8b**) were able to attenuate the antinociceptive effects of the cannabinoid agonist **21** in the tail-flick assay. It remains to be determined if the differences in potencies in vivo can be attributed to differences in biodistribution or metabolism of the various ligands. Nevertheless, these results suggest that these bivalent compounds, despite their high molecular weight, are able to attenuate nociceptive responses by central and or peripheral mechanisms by antagonizing the CB1 receptor complexes.

In summary, a series of bivalent ligands featuring two pharmacophores of **1** and their corresponding monovalent ligands were designed and synthesized to target CB1 receptor homodimers. Biological characterization of these compounds in radioligand binding and functional assays established that the length and the composition of the linker are crucial for the affinities and potencies of the bivalent ligands. Selected bivalent ligands and monovalent ligands were able to attenuate nociceptive effects of CB1 agonist **21**. Although the results suggest possible binding of the bivalent ligands to CB1 receptor homodimers, the possibility of these ligands binding to different sites on a single receptor cannot be ruled out at the present time. However, previous studies using saturation binding experiments with various radioligands do not support high-affinity secondary binding sites on the CB1 receptor providing indirect support for these ligands binding to receptor homodimers or oligomers.[54] Further evaluation of this bivalent ligand approach of CB1 receptor dimerization or oligomerization is clearly needed and may serve as the basis for development of new medications.

Experimental Section

Chemistry. Reactions were conducted under N_2 atmospheres using oven-dried glassware. All solvents and chemicals used were reagent grade. Anhydrous tetrahydrofuran, dichloromethane, and *N*,*N*-dimethylformamide (DMF) were purchased from Aldrich and used as such. Unless otherwise mentioned, all reagents and chemicals were purchased from commercial vendors and used as received. Flash column chromatography was carried out on a Teledyne ISCO CombiFlash Companion system using RediSep Rf prepacked columns. Purity and characterization of compounds were established by a combination of HPLC, TLC, gas chromatography−mass spectrometry (GC−MS), and NMR analytical techniques described below. ^{1}H and ^{13}CNMR spectra were recorded on a Bruker Avance DPX-300 (300 MHz) spectrometer and were determined in $CHCl_3$-*d* or MeOH-d_4 with tetramethylsilane (TMS) (0.00 ppm) or solvent peaks as the internal reference unless otherwise noted. Chemical shifts are reported in ppm relative to the solvent signal, and coupling constant (*J*) values are reported in hertz (Hz). Thin-layer chromatography (TLC) was performed on EMD precoated silica gel 60 F254 plates, and spots were visualized with UV light or I_2 detection. Low-resolution mass spectra were obtained using a Waters Alliance HT/Micromass ZQ system (ESI). High-resolution mass spectra were obtained in the Mass Spectrometry Laboratory, Department of Chemistry, University of Michigan. All test compounds were greater than 95% pure as determined by HPLC on an Agilent 1100 system using an Agilent Zorbax SB-Phenyl, 2.1 mm × 150 mm, 5 μm column with gradient elution using the mobile phases (A) H_2O containing 0.1% CF_3COOH and (B) MeCN. A flow rate of 0.5 mL/min was used for **5a**−**f** and **7a**−**d** and 1.0 mL/min for **6a**−**f** and **8a**−**d**.

15c,**d** and 1**8a**,**b** were purchased from Aldrich and were used as such.

5-(4-Chlorophenyl)-*N*-{13-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazol-3-yl]-13-oxo-3,6,9-trioxa-12-azatridec-1-yl}-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (3). Benzotriazole-1-yl-oxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) (116 mg, 0.262 mmol) was added to a solution of acid **9** (100 mg, 0.262 mmol) in 15 mL of THF. After 5 min, 1,11-diamino-3,6,9-trioxaundecane (30 mg, 0.157 mmol) was added. The mixture was stirred at room temperature for 1 h. The solvent was removed, and the resulting slurry was diluted with saturated aqueous $NaHCO_3$ and extracted with ethyl acetate (2 × 30 mL). The combined organic layers were washed with brine and dried. The residue was purified on silica using MeOH−$CHCl_3$−NH_4OH and EtOAc to give **3** (95 mg, 78.9%) as a solid. ^{1}H NMR ($CDCl_3$) δ 2.38 (s, 6H), 3.58 (m, 16H), 7.05 (d, J = 9.0, 4H), 7.28 (m, 8H), 7.41 (s, 2H). MS: $C_{25}H_{29}Cl_3N_4O_4$, $[M + H]^+$ 555.2.

Methyl *N*-{[5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazol-3-yl]carbonyl}glycinate (10). To a solution of acid **9** (2 g, 5.24 mmol) in 60 mL of CH_2Cl_2 was added sequentially HOBt (0.78 g, 5.76 mmol), EDCI (1.1 g, 5.76 mmol), and glycine methyl ester hydrochloride (0.66 g, 5.24 mmol). The mixture was stirred at room temperature for 15 min before Et_3N was added. The mixture was stirred for 12 h. The mixture was diluted with CH_2Cl_2 (100 mL) and washed with 1 N HCl, $NaHCO_3$, and then brine. The organic layer was dried with Na_2SO_4 and concentrated to give **10** as a white solid. ^{1}H NMR ($CDCl_3$) δ 2.36 (s, 3H), 3.78 (s, 3H), 4.22 (d, J = 5.7, 2H), 7.05 (d, J = 6.6, 2H), 7.30 (m, 4H), 7.40 (t, J = 3.0, 1H), 7.43 (s, 1H). The product was of sufficient purity and was used in the next step without further purification.

***N*-{[5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazol-3-yl]carbonyl}glycine (11).** A solution of **10** in 30 mL of

MeOH and 30 mL of 2 N NaOH was stirred at room temperature for 16 h. The solvent was concentrated in vacuo, and the resulting solution was washed with ether. The aqueous solution was acidified with 6 N HCl and then extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with water, brine and dried with Na_2SO_4. The solvent was removed in vacuo to give **11** (2.09 g, 90.9% over both steps). ^{1}H NMR ($CDCl_3$) δ 2.35 (s, 3H), 4.26 (d, J = 6.0, 2H), 7.06 (d, J = 9.0, 2H), 7.31 (m, 4H), 7.42 (s, 1H), 7.58 (t, 3.0, 1), 10.78 (bs, 1H).

***N*-{[5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazol-3-yl]carbonyl}glycylglycine (12).** Following the procedure for the preparation of **10**, **11** was coupled to glycine methyl ester hydrochloride to provide the methyl ester in 69.5% yield. ^{1}H NMR ($CDCl_3$) δ 2.36 (s, 3H), 3.75 (s, 3H), 4.07 (d, J = 6.0, 2H), 4.16 (d, J = 6.0, 2H), 6.77 (t, J = 3.0, 1H), 7.07 (d, J = 6.0, 2H), 7.29 (m, 4H), 7.43 (s, 1H), 7.53 (t, J = 3.0, 1H).

A solution of the above methyl ester (200 mg, 0.40 mmol) and LiOH (25 mg, 1.2 mmol) in 10 mL of THF−MeOH (3:1) and 2 mL of water was stirred at room temperature for 12 h. The mixture was acidified with 3 N HCl and extracted with EtOAc (2 × 25 mL). The combined organic layers were washed with water, brine and dried with Na_2SO_4. The solvent was evaporated to give **12** (175 mg, 88.4%) as a white solid. ^{1}H NMR ($CDCl_3$) δ 2.31 (s, 3H), 3.78 (s, 2H), 4.09 (s, 2H), 7.19 (d, J = 8.4, 2H), 7.37 (d, J = 8.4, 2H), 7.46−7.56 (m, 3H).

***N*-{[5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazol-3-yl]carbonyl}glycyl-*N*-(2-aminoethyl)glycinamide (4).** To a solution of **12** (140 mg, 0.28 mmol) in THF at room temperature was added BOP (125.0 mg, 0.28 mmol) and ethylenediamine (9.0 μL, 1.41 mmol). The mixture was stirred for 15 min before Et_3N was added. The mixture was stirred for 12 h. The reaction was quenched with water and extracted with EtOAc (2 × 40 mL). The combined organic layers were washed with 1 N HCl, saturated $NaHCO_3$, and brine and then dried with Na_2SO_4. The solvent was removed and the residue was purified on silica gel using MeOH−$CHCl_3$−NH_4OH and EtOAc to give **4** (35 mg, 34.5%) as a solid. ^{1}H NMR ($CDCl_3$) δ 2.31 (s, 3H), 2.87 (d, J = 6.0, 2H), 3.34 (d, J = 6.0, 2H), 3.96 (d, J = 6.0, 2H), 4.08 (d, J = 6.0, 2H), 7.06 (m, 3H), 7.20−7.40 (m, 5H), 7.42 (s, 1H), 7.80 (t, J = 3.0, 1H). MS: $C_{23}H_{23}Cl_3N_6O_3$, $[M + H]^+$ 537.4.

9-Bromononanenitrile (15e). Sodium cyanide (3.6 g, 73.5 mmol) was added in portions to a solution of 1,8-dibromooctane (**13**) (20 g, 73.5 mmol) in 50 mL of DMSO at 60 °C. After 30 min, the reaction was stopped and the mixture was allowed to cool to room temperature. The mixture was diluted with 200 mL of diethyl ether and 200 mL of hexane and then washed with water (2 × 50 mL). The organic layer was separated, dried with sodium sulfate, and concentrated. The resulting slurry was purified on silica using MeOH/CH_2Cl_2 (1:9) to give **15e** (7.16 g, 44.7%) as a colorless oil. ^{1}H NMR ($CDCl_3$) δ 1.35 (t, J = 7.5, 3H), 1.82 (s, 3H), 4.32 (q, J = 7.5, 2H), 7.24 (d, J = 9.0, 1H), 7.37 (d, J = 7.5, 1H), 7.48 (s, 1H).

11-Bromoundecanenitrile (15f). 15f (6.95 g, 42.4%) was obtained from 1,10-dibromodecane (**14**) (20 g, 66.6 mmol) as an oil. ^{1}H NMR ($CDCl_3$) δ 1.15−1.50 (m, 12H), 1.65 (m, 2H), 1.84 (m, 2H), 3.34 (t, J = 7.5, 2H), 3.41 (t, J = 6.0, 2H).

5,5′-(Benzylimino)dipentanenitrile (16c). A mixture of benzylamine (0.5 g, 4.67 mmol), potassium carbonate (1.94 g, 14.0 mmol), and potassium iodide (0.27 g, 1.63 mmol) was heated to 115 °C. A solution of 5-bromopentanenitrile in 1-butanol was added dropwise. The resulting mixture was kept at 115 °C for 20 h. The mixture was allowed to cool to room temperature and then filtered. The solid was washed with diethyl ether (2 × 30 mL). The combined organic layers were extracted with 3 N HCl (2 × 20 mL). The aqueous layer was washed with ether and basified with sodium carbonate. The resulting solution was then extracted with ether (3 × 40 mL). The combined organic layers were dried with Na_2SO_4 and concentrated to give **16c** (1.02 g, 81.1%) as an oil. ^{1}H NMR ($CDCl_3$) δ 1.50−1.70 (m, 8H), 2.26 (t, J = 6.6, 4H), 2.42 (t, J = 6.3, 4H), 3.51 (s, 2H), 7.15−7.32 (m, 5H). The product was of sufficient purity and was used in the next step without further purification.

7,7′-(Benzylimino)diheptanenitrile (16d). 16d (1.43 g, 94.1%) was obtained from benzylamine (0.5 g, 4.67 mmol) and 7-bromoheptanenitrile (1.86 g, 9.80 mmol) as a colorless oil. ^{1}H NMR ($CDCl_3$) δ 1.20−1.65 (m, 16H), 2.29 (t, J = 6.9, 4H), 2.39 (t, J = 6.9, 4H), 3.52 (s, 2H), 7.29 (m, 5H).

9,9′-(Benzylimino)dinonanenitrile (16e). 16e (1.79 g, 100%) was obtained from benzylamine (0.5 g, 4.67 mmol) and **15e** (2.04 g, 9.33 mmol) as an oil. ^{1}H NMR ($CDCl_3$) δ 1.20−1.70 (m, 24H), 2.20−2.45 (m, 8H), 3.51 (s, 2H), 2.24 (m, 5H).

11,11′-(Benzylimino)diundecanenitrile (16f). 16f (2.0 g, 84.8%) was obtained from benzylamine (0.7 g, 6.53 mmol) and **15f** (3.38 g, 13.72 mmol). ^{1}H NMR ($CDCl_3$) δ 1.20−1.50 (m, 24H), 1.65 (m, 4H), 1.83 (m, 4H), 2.35 (t, J = 7.2, 4H), 2.90 (m, 4H), 4.16 (s, 2H), 7.43 (m, 3H), 7.64 (m, 2H).

***N*-(5-Aminopentyl)pentane-1,5-diamine (18c).** A suspension of **16c** (0.5 g, 1.86 mmol) and Raney nickel (0.5 g) in ethanol (40 mL), THF (10 mL), and 2 N sodium hydroxide (8 mL) was stirred under hydrogen (50 psi) for 20 h. The suspension was filtered through Celite and concentrated. The resulting slurry was diluted with water (40 mL) and then extracted with CH_2Cl_2 (2 × 50 mL). The combined organic layers were washed with brine and dried over Na_2SO_4 to give **17c** as an off-white oil. **17c** was used in the next step without purification.

A suspension of **17c** (0.35 g, 1.25 mmol), 10% palladium on carbon (40 mg) in ethanol (15 mL), and acetic acid (5 mL) was stirred under 50 psi of hydrogen for 3 h. The suspension was filtered through Celite, and the filtrate was concentrated. To the resulting slurry was added 2 N NaOH (20 mL), and extraction was with CH_2Cl_2 (2 × 30 mL). The combined organic layers were washed with water and dried with Na_2SO_4. The solvent was evaporated in vacuo to give **18c** (228 mg, 91.1% over both steps) as a clear oil. ^{1}H NMR ($CDCl_3$) δ 1.15−1.55 (m, 12H), 2.53 (t, J = 6.9, 4H), 2.62 (t, J = 6.6, 4H).

***N*-(7-Aminoheptyl)heptane-1,7-diamine (18d).** Following the procedure for the synthesis of **18c**, **18d** (0.85 g, 94.6%) was obtained from **16d** (1.2 g, 3.69 mmol). ^{1}H NMR ($CDCl_3$) δ 1.15−1.50 (m, 20H), 2.52 (t, J = 7.2, 4H), 2.61 (t, J = 6.9, 4H).

***N*-(9-Aminononyl)nonane-1,9-diamine (18e).** Following the procedure for the synthesis of **18c**, **18e** (0.425 g, 77.5%) was obtained from **16e** (0.7 g, 1.83 mmol). ^{1}H NMR ($CDCl_3$) δ 1.20−1.55 (m, 28H), 2.57 (t, J = 7.2, 4H), 2.66 (t, J= 6.9, 4H).

***N*-(11-Aminoundecyl)undecane-1,11-diamine (18f).** Following the procedure for the synthesis of **18c**, **18f** (0.34 g, 84.1%) was obtained from **16f** (0.5 g, 1.14 mmol). ^{1}H NMR ($CDCl_3$) δ 1.10−1.50 (m, 36H), 2.56 (t, J= 7.5, 4H), 2.62 (t, J = 7.2, 4H).

***N*,*N*′-(Iminodiethane-2,1-diyl)bis[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide] (5a).** A solution of acid **9** (0.2 g, 0.52 mmol) and carbonyldiimidazole (85 mg, 0.52 mmol) in 5 mL of CH_2Cl_2 was stirred at room temperature for 1 h. TLC showed the complete consumption of the starting material. Triamine **18a** (28 μL, 0.26 mmol) was added, and the mixture was allowed to stir at room temperature for 3 h. The mixture was diluted with CH_2Cl_2 and washed sequentially with $NaHCO_3$, water, and brine. The solution was dried with Na_2SO_4 and concentrated. The resulting slurry was purified on silica using $CHCl_3$−MeOH−NH_4OH (80:18:2) and EtOAc to give **5a** (0.13 g, 61.1%) as a white solid. ^{1}H NMR ($CDCl_3$) δ 2.35 (s, 6H), 2.90 (t, J = 6.0, 4H), 3.52 (dt, J_1 = J_2 = 6.0, 4H), 7.05 (d, J = 6.0, 4H), 7.22−7.30 (m, 10H), 7.40 (s, 2H). HRMS: $C_{38}H_{31}Cl_6N_7O_2$, $[M + H]^+$ calcd 828.0749, found 828.0768.

***N*,*N*′-(Iminodipropane-3,1-diyl)bis[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide] (5b).** Following the procedure for the preparation of **5a**, **5b** was obtained from **18b** in 49.5% yield. ^{1}H NMR ($CDCl_3$) δ 1.75 (m, 4H), 2.35 (s, 6H), 2.72 (t, J = 6.0, 4H), 3.45 (dt, J_1 = 9.0, J_2 = 6.0, 4H), 7.05 (d, J = 6.0, 4H), 7.28 (m, 8H), 7.40 (s, 2H), 7.54 (t, J = 3.0, 2H). HRMS: $C_{40}H_{35}Cl_6N_7O_2$, $[M + H]^+$ calcd 856.1062, found 856.1076.

***N*,*N*′-(Iminodipentane-5,1-diyl)bis[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide] (5c).** Following the procedure for the preparation of **5a**, **5c** was obtained from **18c** in 42.5% yield. ^{1}H NMR ($CDCl_3$) δ 1.37−1.64 (m, 12H), 2.37 (s, 6H), 2.59 (t, J = 6.0, 4H), 3.41 (dt, J_1 = 9.0, J_2 = 6.0, 4H), 6.96 (t, J = 3.0, 2H), 7.06 (d, J = 6.0, 4H), 7.26 (m, 8H), 7.43 (s, 2H). HRMS: $C_{44}H_{43}Cl_6N_7O_2$, $[M + H]^+$ calcd 912.1688, found 912.1679.

***N*,*N*′-(Iminodiheptane-7,1-diyl)bis[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide] (5d).** Following the procedure for the preparation of **5a**, **5d** was obtained from **18d** in 55.6% yield. ^{1}H NMR ($CDCl_3$) δ 1.34−1.70 (m, 20H) 2.37 (s, 6H), 2.56 (t, J = 6.0, 4H), 3.41 (dt, J_1 = 6.9, J_2 = 6.6, 4H), 6.95 (t, J = 3.0, 2H), 7.05 (d, J = 6.0, 4H), 7.29 (m, 8H), 7.43 (s, 2H). HRMS: $C_{48}H_{51}Cl_6N_7O_2$, $[M + H]^+$ calcd 968.2314, found 968.2321.

***N*,*N*′-(Iminodinonane-9,1-diyl)bis[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide] (5e).** Following the procedure for the preparation of **5a**, **5e** was obtained from **18e** in 42.8% yield. ^{1}H NMR ($CDCl_3$) δ 1.26−1.59 (m, 28H), 2.37 (s, 6H), 2.60 (t, J = 6.0, 4H), 3.40 (dt, J_1 = 6.6, J_2 = 6.0, 4H), 6.95 (t, J = 3.0, 2H), 7.28 (m, 8H), 7.43 (s, 2H). HRMS: $C_{52}H_{59}Cl_6N_7O_2$, $[M + H]^+$ calcd 1024.2940, found 1024.2972.

***N*,*N*′-(Iminodiundecane-11,1-diyl)bis[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide] (5f).** Following the procedure for the preparation of **5a**, **5f** was obtained from **18f** in 38.9% yield. ^{1}H NMR ($CDCl_3$) δ 1.25−1.61 (m, 36H), 2.37 (s, 6H), 2.61 (t, J = 7.5, 4H), 3.40 (dt, J_1 = 6.9, J_2 = 6.6, 4H), 6.96 (t, J = 6.0, 2H), 7.06 (d, J = 8.4, 4H), 7.29 (m, 8H), 7.42 (s, 2H). HRMS: $C_{56}H_{67}Cl_6N_7O_2$, $[M + H]^+$ calcd 1080.3566, found 1080.3590.

***N*-{2-[(2-Aminoethyl)amino]ethyl}-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (7a).** A solution of acid **9** (50 mg, 0.13 mmol) and carbonyldiimidazole (21 mg, 0.13 mmol) in 5 mL of CH_2Cl_2 was stirred at room temperature for 30 min. TLC showed the complete consumption of starting acid. This suspension was then added to a solution of triamine **18a** (41 mg, 0.39 mmol) dropwise. The resulting clear solution was allowed to stir at room temperature for 3 h. The mixture was diluted with CH_2Cl_2 and washed sequentially with $NaHCO_3$, water, and brine. The solution was dried with Na_2SO_4 and concentrated. The resulting slurry was purified on silica using MeOH−$CHCl_3$−NH_4OH (80:18:2) and EtOAc to give **5a** (47 mg, 89.0%) as a solid. ^{1}H NMR ($CDCl_3$) δ 2.36 (s, 3H), 2.72 (t, J = 5.7, 2H), 2.80 (t, J = 4.8, 2H), 2.87 (t, J = 6.0, 2H), 3.53 (dt, J_1 = J_2 = 6.0, 2H), 7.05 (d, J = 6.0, 2H), 7.28 (m, 5H), 7.42 (s, 1H). HRMS: $C_{21}H_{22}Cl_3N_5O$, $[M + H]^+$ calcd 466.0968, found 466.0971.

***N*-{3-[(3-Aminopropyl)amino]propyl}-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (7b).** Following the procedure for the preparation of **7a**, **7b** was obtained from **18b** in 67.9% yield. ^{1}H NMR ($CDCl_3$) δ 1.64 (m, 2H), 1.79 (m, 2H), 2.37 (s, 3H), 2.67−2.77 (m, 6H), 3.53 (dt, J_1 = 5.7, J_2 = 5.4, 2H), 7.05 (d, J = 8.4, 2H), 7.30 (m, 4H), 7.42 (s, 1H), 7.56 (m, 1H). HRMS: $C_{23}H_{26}Cl_3N_5O$, $[M + H]^+$ calcd 494.1281, found 494.1284.

***N*-{5-[(5-Aminopentyl)amino]pentyl}-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (7c).** Following the procedure for the preparation of **7a**, **7c** was obtained from **18c** in 44.9% yield. ^{1}H NMR ($CDCl_3$) δ 1.36−1.60 (m, 12H), 2.37 (s, 3H), 2.59−2.72 (m, 6H), 3.43 (dt, J_1 = 9.3, J_2 = 6.6, 2H), 6.95 (t, J = 3.0, 1H), 7.06 (d, J = 8.4, 2H), 7.29 (m, 4H), 7.43 (s, 1H). HRMS: $C_{27}H_{34}Cl_3N_5O$, $[M + H]^+$ calcd 550.1907, found 550.1909.

***N*-{7-[(7-Aminoheptyl)amino]heptyl}-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (7d).** Following the procedure for the preparation of **7a**, **7d** was obtained from **18d** in 35.2% yield. ^{1}H NMR ($CDCl_3$) δ 1.26−1.62 (m, 20H), 2.38 (s, 3H), 2.56 (m, 4H), 2.67 (t, J = 6.6, 2H), 3.41 (dt, J_1 = 6.9, J_2 = 6.6, 2H), 6.96 (t, J = 3.0, 1H), 7.06 (d, J = 6.9, 2H), 7.29 (m, 4H), 7.43 (s, 1H). HRMS: $C_{31}H_{42}Cl_3N_5O$, $[M + H]^+$ calcd 606.2533, found 606.2536.

***N*-{9-[(9-Aminononyl)amino]nonyl}-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (7e).** Following the procedure for the preparation of **7a**, **7e** was obtained from **18e** in 47.2% yield. ^{1}H NMR ($CDCl_3$) δ 1.18−1.62 (m, 28H), 2.38 (s, 3H), 2.58 (t, J = 7.2, 4H), 2.67 (t, J = 6.9, 2H), 3.40 (dt, J_1 = 6.9, J_2 = 6.6, 2H), 6.96 (t, J = 3.0, 1H), 7.28 (m, 4H), 7.43 (s, 1H). HRMS: $C_{35}H_{50}Cl_3N_5O$, $[M + H]^+$ calcd 662.3159, found 662.3150.

***N*-{11-[(11-Aminoundecyl)amino]undecyl}-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (7f).** Following the procedure for the preparation of **7a**, **7f** was obtained from **18f** in 46.7% yield. ^{1}H NMR ($CDCl_3$) δ 1.20−1.65 (m, 36H), 2.38 (s, 3H), 2.58 (t, J = 7.2, 4H), 2.67 (t, J = 6.9, 2H), 3.40 (dt, J_1 = 6.9, J_2 = 6.6, 2H), 6.95 (t, J = 3.0, 1H), 7.05 (d, J = 8.4, 7.28 (m, 4H), 7.43 (s, 1H). HRMS: $C_{39}H_{58}Cl_3N_5O$, $[M + H]^+$ calcd 718.3785, found 718.3784.

5,5′-(Methylimino)dipentanenitrile (19a). A pressure tube equipped with a mixture of methylamine hydrochloride (1 g, 16 mmol), **15c** (3.7 mL, 32 mmol), potassium carbonate (4.4 g, 32 mmol), and potassium iodide (0.53 g, 3.2 mmol) in 20 mL of ethanol was heated to 110 °C for 16 h. The mixture was cooled to room temperature, and the solvent was removed. The resulting slurry was partitioned between ethyl acetate and water. The organic layer was washed with brine and dried. The resulting residue was purified by chromatography on silica gel to give **19a** (1.24 g, 40.1%) as an off-white oil. ^{1}H NMR ($CDCl_3$) δ 1.55−1.85 (m, 8H), 2.19 (s, 3H), 2.38 (m, 8H).

7,7′-(Methylimino)diheptanenitrile (19b). 19b was synthesized from **15d** in 48.8% yield following the procedure for **19a**. ^{1}H NMR ($CDCl_3$) 1.25−1.70 (m, 16H), 2.18 (s, 3H), 2.33 (m, 8H).

9,9′-(Methylimino)dinonanenitrile (19c). 19c was synthesized from **15e** in 55.0% yield following the procedure for **19a**. ^{1}H NMR ($CDCl_3$) 1.25−1.50 (m, 20H), 1.65 (m, 4H), 2.19 (s, 3H), 2.31 (m, 8H).

11,11′-(Methylimino)diundecanenitrile (19d). 19d was synthesized from **15f** in 42.5% yield following the procedure for **19a**. ^{1}H NMR ($CDCl_3$) 1.20−1.50 (m, 24H), 1.66 (m, 4H), 1.85 (m, 4H), 2.36 (t, J = 3.9, 4H), 2.78 (s, 3H), 3.01 (t, J = 8.4, 4H).

***N*-(5-Aminopentyl)-*N*-methylpentane-1,5-diamine (20a). 20a** was synthesized from **19a** in 59.0% yield following the procedure for **17c**. ^{1}H NMR ($CDCl_3$) δ 1.15−1.55 (m, 12H), 2.20 (s, 3H), 2.31 (t, J = 7.5, 4H), 2.69 (t, J = 6.9, 4H).

***N*-(7-Aminoheptyl)-*N*-methylheptane-1,7-diamine (20b). 20b** was synthesized from **19b** in 73.8% yield following the procedure for **17c**. ^{1}H NMR ($CDCl_3$) δ 1.20−1.50 (m, 24H), 2.18 (s, 3H), 2.29 (t, J = 7.5, 4H), 2.67 (t, J = 6.9, 4H).

***N*-(9-Aminononyl)-*N*-methylnonane-1,9-diamine (20c). 20c** was synthesized from **19c** in 99.0% yield following the procedure for **17c**. ^{1}H NMR ($CDCl_3$) δ 1.20−1.55 (m, 28H), 2.19 (s, 3H), 2.29 (t, J = 7.8, 4H), 2.67 (t, J = 6.9, 4H).

***N*-(11-Aminoundecyl)-*N*-methylundecane-1,11-diamine (20d). 20d** was synthesized from **19d** in 79.0% yield following the procedure for **17c**. ^{1}H NMR ($CDCl_3$) δ 1.20−1.50 (m, 36H), 2.19 (s, 3H), 2.29 (t, J = 7.8, 4H), 2.67 (t, J = 6.9, 4H).

***N*,*N*′-[(Methylimino)dipentane-5,1-diyl]bis[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide] (6a).** Following the procedure for the preparation of **5a**, **6a** was obtained from **20a** in 50.2% yield. ^{1}H NMR ($CDCl_3$) δ 1.37−1.65 (m, 12H), 2.24 (s, 3H), 2.38 (m, 10H), 3.41 (dt, J_1 = 6.6, J_2 = 6.0, 4H), 7.00 (t, J = 3.0, 2H), 7.06 (d, J = 6.0, 4H), 7.28 (m, 8H), 4.23 (s, 2H). HRMS: $C_{45}H_{45}Cl_6N_7O_2$, $[M + H]^+$ calcd 926.1844, found 926.1866.

***N*,*N*′-[(Methylimino)diheptane-7,1-diyl]bis[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide] (6b).** Following the procedure for the preparation of **5a**, **6b** was obtained from **20b** in 40.3% yield. ^{1}H NMR ($CDCl_3$) δ 1.26−1.60 (m, 20H), 2.18 (s, 3H), 2.28 (t, J = 6.0, 4H), 2.37 (s, 6H), 3.41 (dt, J_1 = 6.6, J_2 = 6.0, 4H), 6.95 (t, J = 3.0, 2H), 7.06 (d, J = 6.0, 4H), 7.28

(m, 8H), 7.42 (s, 2H). HRMS: $C_{49}H_{53}Cl_6N_7O_2$, $[M + H]^+$ calcd 982.2470, found 982.2482.

***N*,*N*′-[(Methylimino)dinonane-9,1-diyl]bis[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide] (6c).** Following the procedure for the preparation of **5a**, **6c** was obtained from **20c** in 53.5% yield. ^{1}H NMR ($CDCl_3$) δ 1.28−1.50 (m, 24H), 1.50−1.65 (m, 4H), 2.19 (s, 3H), 2.29 (t, J = 7.8, 4H), 2.38 (s, 6H), 3.40 (dt, J_1 = 6.9, J_2 = 6.6, 4H), 6.96 (t, J = 3.0, 2H), 7.06 (d, J = 8.4, 4H), 7.29 (m, 8H), 7.43 (s, 2H). HRMS: $C_{53}H_{61}Cl_6N_7O_2$, $[M + H]^+$ calcd 1038.3096, found 1038.3094.

***N*,*N*′-[(Methylimino)diundecane-11,1-diyl]bis[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide] (6d).** Following the procedure for the preparation of **5a**, **6d** was obtained from **20d** in 43.8% yield. ^{1}H NMR ($CDCl_3$) δ 1.20−1.65 (m, 36H), 2.29 (s, 3H), 2.41 (m, 10H), 3.42 (dt, J_1 = 9.0, J_2 = 6.0, 4H), 6.94 (t, J = 3.0, 2H), 7.05 (d, J = 9.0, 4H), 7.28 (m, 8H), 7.42 (s, 2H). HRMS: $C_{57}H_{69}Cl_6N_7O_2$, $[M + H]^+$ calcd 1094.3722, found 1094.3715.

***N*-{5-[(5-Aminopentyl)(methyl)amino]pentyl}-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (8a).** Following the procedure for the preparation of **7a**, **8a** was obtained from **20a** in 60.8% yield. ^{1}H NMR ($CDCl_3$) δ 1.22−1.70 (m, 12H), 2.20 (s, 3H), 2.32 (t, J = 7.5, 4H), 2.37 (s, 3H), 2.69 (t, J = 6.9, 2H), 2.42 (dt, J_1 = 6.9, J_2 = 6.6, 2H), 6.99 (t, J = 3.0, 1H), 7.06 (d, J = 6.6, 2H), 7.29 (m, 4H), 7.43 (s, 1H). HRMS: $C_{28}H_{36}Cl_3N_5O$, $[M + H]^+$ calcd 564.2064, found 564.2073.

***N*-{7-[(7-Aminoheptyl)(methyl)amino]heptyl}-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (8b).** Following the procedure for the preparation of **7a**, **8b** was obtained from **20b** in 29.5% yield. ^{1}H NMR ($CDCl_3$) δ 1.20−1.65 (m, 20H), 2.19 (s, 3H), 2.29 (t, J = 7.8, 4H), 2.38 (s, 3H), 2.67 (t, J = 6.6, 2H), 2.41 (dt, J_1 = 6.9, J_2 = 6.6, 2H), 6.95 (t, J = 3.0, 1H), 7.06 (d, J = 6.9, 2H), 7.28 (m, 4H), 7.43 (s, 1H). HRMS: $C_{32}H_{44}Cl_3N_5O$, $[M + H]^+$ calcd 620.2690, found 620.2687.

***N*-{9-[(9-Aminononyl)(methyl)amino]nonyl}-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (8c).** Following the procedure for the preparation of **7a**, **8c** was obtained from **20c** in 34.9% yield. ^{1}H NMR ($CDCl_3$) δ 1.20−1.65 (m, 28H), 2.19 (s, 3H), 2.29 (t, J = 9.0, 4H), 2.38 (s, 3H), 2.67 (s, 3H), 3.41 (dt, J_1 = 9.0, J_2 = 6.0, 2H), 6.95 (t, J = 3.0, 1H), 7.05 (d, J = 9.0, 2H), 7.28 (m, 4H), 7.43 (s, 1H). HRMS: $C_{36}H_{52}Cl_3N_5O$, $[M + H]^+$ calcd 676.3316, found 676.3312.

***N*-{11-[(11-Aminoundecyl)(methyl)amino]undecyl}-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (8d).** Following the procedure for the preparation of **7a**, **8d** was obtained from **20b** in 40.6% yield. ^{1}H NMR ($CDCl_3$) δ 1.20−1.60 (m, 36H), 2.20 (s, 3H), 2.29 (t, J = 7.8, 4H), 2.38 (s, 3H), 3.40 (dt, J_1 = 6.9, J_2 = 6.6, 2H), 6.95 (t, J = 3.0, 1H), 7.07 (d, J = 6.6, 2H), 7.29 (m, 4H), 7.43 (s, 1H). HRMS: $C_{40}H_{60}Cl_3N_5O$, $[M + H]^+$ calcd 732.3942, found 732.3947.

Receptor Binding Assays. CB1 and CB2 Receptor Binding Assays. The CB1 receptor binding assay involved membranes isolated from a HEK-293 expression system, whereas the CB2 receptor was expressed in CHO-K1 cells (Sigma-Aldrich Chemical Co., St. Louis, MO). The methods used for performing binding assays in transfected cells expressing human CB1 or CB2 receptors were similar to those previously described for rat brain membrane preparations.[26,36] Binding was initiated with the addition of 40 μg of cell membrane proteins to assay tubes containing [^{3}H]**21** (~130 Ci/mmol) or [^{3}H]**1** (~22.4 Ci/mmol), a test compound (for displacement studies), and a sufficient quantity of buffer (50 mM Tris·HCl, 1 mM EDTA, 3 mM $MgCl_2$, 5 mg/mL BSA, pH 7.4) to bring the total incubation volume to 0.5 mL. All assays were performed in polypropylene test tubes. In the displacement assays, the concentrations of [^{3}H]**21** and [^{3}H]**1** were 7.2 and 20 nM, respectively. Nonspecific binding was determined by the inclusion of 10 μM unlabeled **21** or **1**. All cannabinoid analogues were prepared by suspension in buffer A from a 1 mg/mL ethanol stock. Following incubation at 30 °C for 1 h, binding was terminated by vacuum filtration through GF/C glass fiber filter plates (Packard, Meriden, CT, pretreated in buffer B for at least 1 h) in a 96-well sampling manifold (Millipore, Bedford, MA). Reaction vessels were washed twice with 4 mL of ice cold buffer (50 mM Tris·HCl, 1 mg/mL BSA). The filter plates were air-dried and sealed on the bottom. Liquid scintillate was added to the wells and the top sealed. After incubation of the plates in cocktail for at least 2 h, the radioactivity present was determined by liquid scintillation spectrometry. Assays were done in duplicate, and results represent combined data from three to six independent experiments. Saturation and displacement data were analyzed by unweighted nonlinear regression of receptor binding data. For displacement studies, curve-fitting and IC_{50} calculation were done with GraphPad Prism (GraphPad Software, Inc., San Diego, CA), which fits the data to one- and two-site models and compares the two fits statistically.

GTP-γ-[^{35}S] Assay. GTP-γ-[^{35}S] assays were performed to determine the ability of target compounds to shift the binding curves of the agonist **21** or **1**. Reaction mixtures consisted of either **21** (2.5 pM to 25 μM) or **1** (10 pM to 100 μM), 20 μM GDP, and 100 pM GTP-γ-[^{35}S] in 50 mM Tris·HCl, pH 7.4, 1 mM EDTA, 5 mM $MgCl_2$, 100 mM NaCl, and 1 mg/mL BSA. The effects of these compounds on agonist binding were compared at 1, 10, and 100 nM vs reactions with no antagonist in a final reaction mixture volume of 0.5 mL. Binding was determined using membrane preparations as previously described. Data analysis was performed using global nonlinear regression analysis of the dose−response curves (Prism, GraphPad), and pA_2 values were calculated. The calculations were performed with the slope of the Schild line constrained to 1, as well as unconstrained, and an F-test ($P < 0.05$) was used to determine the best model.

Calcium Mobilization Assay. Calcium mobilization was performed in CHO cells coexpressing Gα16 protein and the human CB1 receptor cDNAs. Activation of CB1 receptor leads to coupling of this receptor to the promiscuous Gα16 protein and consequent mobilization of intracellular calcium. In the assay, the apparent agonist dissociation equilibrium constant (K_e) of each compound was determined by running a six-point half-log **21** concentration response curve in the presence and absence of a single concentration of antagonist.[55] The concentration of antagonist was chosen such that it caused at least a 2-fold increase (shift to the right) in the **21** curve but did not exceed 10 μM to retain pharmacological relevance. A three-parameter logistic equation was fit to the concentration response data with Prism (GraphPad Software; San Diego, CA) to calculate K_e. These values were reported as the mean ± SEM from at least three independent experiments. **1** was employed as the positive control (antagonist) for inhibition of CB1 activity.

Acknowledgment. This work was supported by the National Institutes of Health/National Institute on Drug Abuse (NIDA) Grants DA019217 (B.F.T.) and DA026582 (Y.Z.) and NIAAA Grants AA017514 and AA019740 (R.M.).

Supporting Information Available: HPLC data of target compounds **5a**−**f**, **6a**−**d**, **7a**−**f**, and **8a**−**d**. This material is available free of charge via the Internet at http://pubs.acs.org.

References

(1) De Petrocellis, L.; Cascio, M. G.; Di Marzo, V. The endocannabinoid system: a general view and latest additions. *Br. J. Pharmacol.* **2004**, *141* (5), 765–774.
(2) Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol. Rev.* **2006**, *58* (3), 389–462.
(3) Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol. Rev.* **2002**, *54* (2), 161–202.

(4) Mackie, K. Cannabinoid receptor homo- and heterodimerization. *Life Sci*. **2005**, *77* (14), 1667–1673.
(5) Wager-Miller, J.; Westenbroek, R.; Mackie, K. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. *Chem. Phys. Lipids* **2002**, *121* (1−2), 83–89.
(6) George, S. R.; O'Dowd, B. F.; Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. *Nat. Rev. Drug Discovery* **2002**, *1* (10), 808–820.
(7) Lee, S. P.; O'Dowd, B. F.; Ng, G. Y.; Varghese, G.; Akil, H.; Mansour, A.; Nguyen, T.; George, S. R. Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell. *Mol. Pharmacol*. **2000**, *58* (1), 120–128.
(8) Franco, R.; Casado, V.; Cortes, A.; Mallol, J.; Ciruela, F.; Ferre, S.; Lluis, C.; Canela, E. I. G-protein-coupled receptor heteromers: function and ligand pharmacology. *Br. J. Pharmacol*. **2008**, *153* (Suppl. 1), S90–98.
(9) Rios, C. D.; Jordan, B. A.; Gomes, I.; Devi, L. A. G-protein-coupled receptor dimerization: modulation of receptor function. *Pharmacol. Ther*. **2001**, *92* (2−3), 71–87.
(10) Minneman, K. P. Heterodimerization and surface localization of G protein coupled receptors. *Biochem. Pharmacol*. **2007**, *73* (8), 1043–1050.
(11) Milligan, G. G protein-coupled receptor dimerization: function and ligand pharmacology. *Mol. Pharmacol*. **2004**, *66* (1), 1–7.
(12) Milligan, G. G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. *Drug Discovery Today* **2006**, *11* (11−12), 541–549.
(13) Daniels, D. J.; Lenard, N. R.; Etienne, C. L.; Law, P. Y.; Roerig, S. C.; Portoghese, P. S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. *Proc. Natl. Acad. Sci. U.S.A*. **2005**, *102* (52), 19208–19213.
(14) Portoghese, P. S. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. *J. Med. Chem*. **2001**, *44* (14), 2259–2269.
(15) Messer, W. S., Jr. Bivalent ligands for G protein-coupled receptors. *Curr. Pharm. Des*. **2004**, *10* (17), 2015–2020.
(16) Peng, X.; Neumeyer, J. L. Kappa receptor bivalent ligands. *Curr. Top. Med. Chem*. **2007**, *7* (4), 363–373.
(17) Zheng, W.; Lei, L.; Lalchandani, S.; Sun, G.; Feller, D. R.; Miller, D. D. Yohimbine dimers exhibiting binding selectivities for human alpha2a- versus alpha2b-adrenergic receptors. *Bioorg. Med. Chem. Lett*. **2000**, *10* (7), 627–630.
(18) Lalchandani, S. G.; Lei, L.; Zheng, W.; Suni, M. M.; Moore, B. M.; Liggett, S. B.; Miller, D. D.; Feller, D. R. Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype. *J. Pharmacol. Exp. Ther*. **2002**, *303* (3), 979–984.
(19) Tamiz, A. P.; Bandyopadhyay, B. C.; Zhang, J.; Flippen-Anderson, J. L.; Zhang, M.; Wang, C. Z.; Johnson, K. M.; Tella, S.; Kozikowski, A. P. Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors. *J. Med. Chem*. **2001**, *44* (10), 1615–1622.
(20) Russo, O.; Berthouze, M.; Giner, M.; Soulier, J. L.; Rivail, L.; Sicsic, S.; Lezoualc'h, F.; Jockers, R.; Berque-Bestel, I. Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers. *J. Med. Chem*. **2007**, *50* (18), 4482–4492.
(21) Meltzer, P. C.; Kryatova, O.; Pham-Huu, D. P.; Donovan, P.; Janowsky, A. The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters. *Bioorg. Med. Chem*. **2008**, *16* (4), 1832–1841.
(22) Christopoulos, A.; Grant, M. K.; Ayoubzadeh, N.; Kim, O. N.; Sauerberg, P.; Jeppesen, L.; El-Fakahany, E. E. Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. *J. Pharmacol. Exp. Ther*. **2001**, *298* (3), 1260–1268.
(23) Rajeswaran, W. G.; Cao, Y.; Huang, X. P.; Wroblewski, M. E.; Colclough, T.; Lee, S.; Liu, F.; Nagy, P. I.; Ellis, J.; Levine, B. A.; Nocka, K. H.; Messer, W. S., Jr. Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists. *J. Med. Chem*. **2001**, *44* (26), 4563–4576.
(24) Beardsley, P. M.; Thomas, B. F. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. *Behav. Pharmacol*. **2005**, *16* (5−6), 275–296.
(25) Bifulco, M.; Grimaldi, C.; Gazzerro, P.; Pisanti, S.; Santoro, A. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. *Mol. Pharmacol*. **2007**, *71* (6), 1445–1456.
(26) Francisco, M. E.; Seltzman, H. H.; Gilliam, A. F.; Mitchell, R. A.; Rider, S. L.; Pertwee, R. G.; Stevenson, L. A.; Thomas, B. F. Synthesis and structure−activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist *N*-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxami de (SR141716). *J. Med. Chem*. **2002**, *45* (13), 2708–2719.
(27) Thomas, B. F.; Francisco, M. E.; Seltzman, H. H.; Thomas, J. B.; Fix, S. E.; Schulz, A. K.; Gilliam, A. F.; Pertwee, R. G.; Stevenson, L. A. Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist *N*-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyra zole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. *Bioorg. Med. Chem*. **2005**, *13* (18), 5463–5474.
(28) Dyck, B.; Goodfellow, V. S.; Phillips, T.; Grey, J.; Haddach, M.; Rowbottom, M.; Naeve, G. S.; Brown, B.; Saunders, J. Potent imidazole and triazole CB1 receptor antagonists related to SR141716. *Bioorg. Med. Chem. Lett*. **2004**, *14* (5), 1151–1154.
(29) Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein-coupled receptor. *Science* **2000**, *289* (5480), 739–745.
(30) Portoghese, P. S.; Larson, D. L.; Sayre, L. M.; Yim, C. B.; Ronsisvalle, G.; Tam, S. W.; Takemori, A. E. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. *J. Med. Chem*. **1986**, *29* (10), 1855–1861.
(31) Neumeyer, J. L.; Zhang, A.; Xiong, W.; Gu, X. H.; Hilbert, J. E.; Knapp, B. I.; Negus, S. S.; Mello, N. K.; Bidlack, J. M. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors. *J. Med. Chem*. **2003**, *46* (24), 5162–5170.
(32) Peng, X.; Knapp, B. I.; Bidlack, J. M.; Neumeyer, J. L. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. *J. Med. Chem*. **2006**, *49* (1), 256–262.
(33) Soriano, A.; Ventura, R.; Molero, A.; Hoen, R.; Casado, V.; Cortes, A.; Fanelli, F.; Albericio, F.; Lluis, C.; Franco, R.; Royo, M. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. *J. Med. Chem*. **2009**, *52* (18), 5590–5602.
(34) Bonger, K. M.; van den Berg, R. J.; Heitman, L. H.; AP, I. J.; Oosterom, J.; Timmers, C. M.; Overkleeft, H. S.; van der Marel, G. A. Synthesis and evaluation of homo-bivalent GnRHR ligands. *Bioorg. Med. Chem*. **2007**, *15* (14), 4841–4856.
(35) Wiley, J. L.; Jefferson, R. G.; Grier, M. C.; Mahadevan, A.; Razdan, R. K.; Martin, B. R. Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation. *J. Pharmacol. Exp. Ther*. **2001**, *296* (3), 1013–1022.
(36) Zhang, Y.; Burgess, J. P.; Brackeen, M.; Gilliam, A.; Mascarella, S. W.; Page, K.; Seltzman, H. H.; Thomas, B. F. Conformationally constrained analogues of *N*-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations. *J. Med. Chem*. **2008**, *51* (12), 3526–3539.
(37) Seltzman, H. H.; Carroll, F. I.; Burgess, J. P.; Wyrick, C. D.; Burch, D. F. Tritiation of SR141716 by metallation-iodination-reduction: tritium-proton nOe study. *J. Labelled Compd. Radiopharm*. **2002**, *45* (1), 59–70.
(38) Howes, R.; Barril, X.; Dymock, B. W.; Grant, K.; Northfield, C. J.; Robertson, A. G.; Surgenor, A.; Wayne, J.; Wright, L.; James, K.; Matthews, T.; Cheung, K. M.; McDonald, E.; Workman, P.; Drysdale, M. J. A fluorescence polarization assay for inhibitors of Hsp90. *Anal. Biochem*. **2006**, *350* (2), 202–213.
(39) Wiley, J. L.; Wang, P.; Mahadevan, A.; Razdan, R. K.; Martin, B. R. Pyrazole Cannabinoids with Non-CB1, Non-CB2 Activity. Presented at the 19th Annual Symposium of the International Cannabinoid Research Society, St. Charles, IL, July 8−11, **2009**.
(40) Daniels, D. J.; Kulkarni, A.; Xie, Z.; Bhushan, R. G.; Portoghese, P. S. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. *J. Med. Chem*. **2005**, *48* (6), 1713–1716.
(41) Xie, Z.; Bhushan, R. G.; Daniels, D. J.; Portoghese, P. S. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. *Mol. Pharmacol*. **2005**, *68* (4), 1079–1086.
(42) Portoghese, P. S.; Edward, E. The role of concepts in structure−activity relationship studies of opioid ligands. *J. Med. Chem*. **1992**, *35* (11), 1927–1937 (Smissman-Bristol-Myers Squibb Award Address) .
(43) Neumeyer, J. L.; Peng, X.; Knapp, B. I.; Bidlack, J. M.; Lazarus, L. H.; Salvadori, S.; Trapella, C.; Balboni, G. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. *J. Med. Chem*. **2006**, *49* (18), 5640–5643.
(44) Bhushan, R. G.; Sharma, S. K.; Xie, Z.; Daniels, D. J.; Portoghese, P. S. A bivalent ligand (KDN-21) reveals spinal delta and kappa

opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. *J. Med. Chem.* **2004**, *47* (12), 2969–2972.
(45) Bonger, K. M.; van den Berg, R. J.; Knijnenburg, A. D.; Heitman, L. H.; Ijzerman, A. P.; Oosterom, J.; Timmers, C. M.; Overkleeft, H. S.; van der Marel, G. A. Synthesis and evaluation of homodimeric GnRHR antagonists having a rigid bis-propargylated benzene core. *Bioorg. Med. Chem.* **2008**, *16* (7), 3744–3758.
(46) Fulton, B. S.; Knapp, B. L.; Bidlack, J. M.; Neumeyer, J. L. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. *Bioorg. Med. Chem. Lett.* **2010**, *20* (5), 1507–1509.
(47) Decker, M.; Fulton, B. S.; Zhang, B.; Knapp, B. I.; Bidlack, J. M.; Neumeyer, J. L. Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. *J. Med. Chem.* **2009**, *52* (23), 7389–7396.
(48) Mathews, J. L.; Fulton, B. S.; Negus, S. S.; Neumeyer, J. L.; Bidlack, J. M. In vivo characterization of (−)(−)MCL-144 and (+)(−)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties. *Neurochem. Res.* **2008**, *33* (10), 2142–2150.
(49) Antony, J.; Kellershohn, K.; Mohr-Andra, M.; Kebig, A.; Prilla, S.; Muth, M.; Heller, E.; Disingrini, T.; Dallanoce, C.; Bertoni, S.; Schrobang, J.; Trankle, C.; Kostenis, E.; Christopoulos, A.; Holtje, H. D.; Barocelli, E.; De Amici, M.; Holzgrabe, U.; Mohr, K. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. *FASEB J.* **2009**, *23* (2), 442–450.
(50) Valant, C.; Sexton, P. M.; Christopoulos, A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. *Mol. Intervensions* **2009**, *9* (3), 125–135.
(51) Mohr, K.; Trankle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational design of dualsteric GPCR ligands: quests and promise. *Br. J. Pharmacol.* **2010**, *159* (5), 997–1008.
(52) Steinfeld, T.; Mammen, M.; Smith, J. A.; Wilson, R. D.; Jasper, J. R. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. *Mol. Pharmacol.* **2007**, *72* (2), 291–302.
(53) Narlawar, R.; Lane, J. R.; Doddareddy, M.; Lin, J.; Brussee, J.; Ijzerman, A. P. Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. *J. Med. Chem.* **2010**, *53* (8), 3028–3037.
(54) Rodriguez-Martin, I.; de Velasco, E. M.; Rodriguez, R. E. Characterization of cannabinoid-binding sites in zebrafish brain. *Neurosci. Lett.* **2007**, *413* (3), 249–254.
(55) Kosterlitz, H. W.; Lees, G. M.; Wallis, D. I.; Watt, A. J. Non-specific inhibitory effects of morphine-like drugs on transmission in the superior cervical ganglion and guinea-pig isolated ileum. *Br. J. Pharmacol.* **1968**, *34* (3), 691P–692P.